Eli Lilly and Company

SWX:LLY Stock Report

Market Cap: CHF 717.1b

Eli Lilly Valuation

Is LLY undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of LLY when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: LLY (CHF805) is trading below our estimate of future cash flow value (CHF1268.49)

Significantly Below Future Cash Flow Value: LLY is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for LLY?

Key metric: As LLY is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for LLY. This is calculated by dividing LLY's market cap by their current earnings.
What is LLY's PE Ratio?
PE Ratio45x
EarningsUS$20.64b
Market CapUS$929.09b

Price to Earnings Ratio vs Peers

How does LLY's PE Ratio compare to its peers?

The above table shows the PE ratio for LLY vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average84x
NOVN Novartis
22.7x9.07%CHF 245.0b
ROG Roche Holding
22.8x11.00%CHF 294.7b
GALD Galderma Group
125.3x26.86%CHF 36.6b
SDZ Sandoz Group
165.1x24.88%CHF 28.9b
LLY Eli Lilly
45x17.85%CHF 929.1b

Price-To-Earnings vs Peers: LLY is good value based on its Price-To-Earnings Ratio (45x) compared to the peer average (84x).

Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Earnings Ratio vs Industry

How does LLY's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
LLY 45.0xIndustry Avg. 24.2xNo. of Companies8PE01632486480+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: LLY is expensive based on its Price-To-Earnings Ratio (45x) compared to the European Pharmaceuticals industry average (24.2x).

Price to Earnings Ratio vs Fair Ratio

What is LLY's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

LLY PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio45x
Fair PE Ratio56.7x

Price-To-Earnings vs Fair Ratio: LLY is good value based on its Price-To-Earnings Ratio (45x) compared to the estimated Fair Price-To-Earnings Ratio (56.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst LLY forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 805.00
CHF 922.67
+14.62%
12.45%CHF 1,151.78CHF 637.32n/a27
Feb ’27CHF 795.00
CHF 886.09
+11.46%
13.62%CHF 1,159.50CHF 595.21n/a27
Jan ’27CHF 850.00
CHF 862.63
+1.49%
16.19%CHF 1,183.61CHF 607.58n/a27
Dec ’26CHF 860.00
CHF 834.17
-3.00%
17.08%CHF 1,207.26CHF 619.73n/a27
Nov ’26CHF 790.00
CHF 739.74
-6.36%
13.58%CHF 957.53CHF 563.26n/a27
Oct ’26CHF 610.00
CHF 707.86
+16.04%
14.84%CHF 948.43CHF 518.05n/a26
Sep ’26CHF 585.00
CHF 710.96
+21.53%
15.43%CHF 952.19CHF 520.10n/a27
Aug ’26CHF 625.00
CHF 770.21
+23.23%
14.37%CHF 958.06CHF 523.31n/a27
Jul ’26CHF 620.00
CHF 761.39
+22.80%
15.01%CHF 951.76CHF 519.87n/a27
Jun ’26CHF 605.00
CHF 785.96
+29.91%
15.09%CHF 979.05CHF 534.77n/a27
May ’26CHF 720.00
CHF 817.24
+13.51%
12.76%CHF 987.20CHF 539.23n/a26
Apr ’26CHF 740.00
CHF 893.15
+20.70%
11.88%CHF 1,051.83CHF 548.01n/a26
Mar ’26CHF 790.00
CHF 899.08
+13.81%
12.84%CHF 1,074.36CHF 559.75n/a26
Feb ’26CHF 745.00
CHF 888.21
+19.22%
14.99%CHF 1,083.76CHF 528.22CHF 795.0026
Jan ’26CHF 690.00
CHF 887.84
+28.67%
15.07%CHF 1,127.79CHF 523.29CHF 850.0027
Dec ’25CHF 660.00
CHF 874.14
+32.44%
14.86%CHF 1,100.58CHF 510.67CHF 860.0027
Nov ’25CHF 750.00
CHF 875.70
+16.76%
13.94%CHF 1,088.25CHF 504.95CHF 790.0027
Oct ’25CHF 750.00
CHF 836.83
+11.58%
13.87%CHF 966.78CHF 487.59CHF 610.0025
Sep ’25CHF 800.00
CHF 839.00
+4.88%
13.93%CHF 977.74CHF 493.12CHF 585.0025
Aug ’25CHF 775.00
CHF 802.85
+3.59%
16.35%CHF 975.83CHF 471.75CHF 625.0026
Jul ’25CHF 830.00
CHF 780.99
-5.90%
14.02%CHF 925.31CHF 485.35CHF 620.0025
Jun ’25CHF 725.00
CHF 770.21
+6.24%
12.73%CHF 924.23CHF 487.86CHF 605.0026
May ’25CHF 690.00
CHF 776.97
+12.60%
13.25%CHF 940.28CHF 496.34CHF 720.0026
Apr ’25CHF 690.00
CHF 716.12
+3.79%
14.10%CHF 898.03CHF 449.02CHF 740.0026
Mar ’25CHF 660.00
CHF 677.98
+2.72%
15.03%CHF 883.24CHF 441.62CHF 790.0027
Feb ’25CHF 550.00
CHF 550.38
+0.07%
13.93%CHF 659.26CHF 371.54CHF 745.0026
CHF 930.11
Fair Value
13.5% undervalued intrinsic discount
27
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/02/17 11:24
End of Day Share Price 2026/02/17 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Eli Lilly and Company is covered by 51 analysts. 28 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David ToungArgus Research Company
Kerry HolfordBerenberg
Courtney BreenBernstein